GSK, Bharat Biotech To Halve Cost Of Malaria Vaccine By 2028

Reuters (6/25, Fick, Rigby) reports that GSK and Bharat Biotech said Wednesday they will cut the price of their malaria vaccine, Mosquirix, “to below $5 per dose by 2028, more than halving its current cost.” GSK is currently “working on a technology transfer to Bharat, and will continue to supply the adjuvant part of the vaccine to Bharat when the Indian drugmaker fully takes over production of the shot by 2028.” GSK said in a statement that the price cut was “driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins.” GSK and Bharat also “said the price reduction showed their commitment to Gavi, which has been funding some of the roll-out of the malaria vaccine.”